Stifel Financial Corp boosted its stake in Quest Diagnostics Inc (NYSE:DGX) by 2.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 53,229 shares of the medical research company’s stock after purchasing an additional 1,153 shares during the quarter. Stifel Financial Corp’s holdings in Quest Diagnostics were worth $4,984,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Parallel Advisors LLC lifted its stake in Quest Diagnostics by 0.9% in the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after purchasing an additional 12 shares in the last quarter. Thrivent Financial For Lutherans lifted its stake in Quest Diagnostics by 2.0% in the 2nd quarter. Thrivent Financial For Lutherans now owns 5,200 shares of the medical research company’s stock worth $578,000 after purchasing an additional 100 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Quest Diagnostics by 3.5% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,894 shares of the medical research company’s stock worth $434,000 after purchasing an additional 131 shares in the last quarter. D.A. Davidson & CO. lifted its stake in Quest Diagnostics by 1.2% in the 2nd quarter. D.A. Davidson & CO. now owns 12,788 shares of the medical research company’s stock worth $1,421,000 after purchasing an additional 147 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Quest Diagnostics by 1.0% in the 2nd quarter. Marshall Wace LLP now owns 17,659 shares of the medical research company’s stock worth $1,960,000 after purchasing an additional 177 shares in the last quarter. Institutional investors and hedge funds own 89.20% of the company’s stock.

DGX has been the topic of several recent research reports. KeyCorp restated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. Wells Fargo & Company decreased their target price on shares of Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research report on Friday, October 20th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Goldman Sachs Group cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and decreased their target price for the company from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, Canaccord Genuity upped their target price on shares of Quest Diagnostics from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. Quest Diagnostics has a consensus rating of “Hold” and an average target price of $106.28.

Quest Diagnostics Inc (NYSE:DGX) opened at $98.99 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.37. The company has a market cap of $13,237.40, a PE ratio of 17.41, a price-to-earnings-growth ratio of 2.02 and a beta of 0.60. Quest Diagnostics Inc has a one year low of $90.10 and a one year high of $112.96.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, October 19th. The medical research company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.37 EPS. sell-side analysts anticipate that Quest Diagnostics Inc will post 5.65 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 9th will be given a $0.45 dividend. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a dividend yield of 1.82%. Quest Diagnostics’s payout ratio is presently 37.74%.

WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/16/stifel-financial-corp-has-4-98-million-position-in-quest-diagnostics-inc-dgx.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related stocks with our FREE daily email newsletter.